Showing results (321-330 of 345) with videos related to
Sort By:
Pageof 35
American Journal of Cancer Research|July 25, 2014
Distinct breast cancer subtypes in women with early-onset disease across racesMandeep Singh, Yi Ding, Li-Ying Zhang, et al.Clinical Breast Cancer|January 18, 2016
Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant ChemotherapyKomal Jhaveri, Eleonora Teplinsky, Deborah Silvera, et al.Cell Death & Disease|September 1, 2018
Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneityNi Ni Moe Myint, Ajay M Verma, Daniel Fernandez-Garcia, et al.PLOS Global Public Health|April 14, 2023
METER (Mental health emergency response) program: Findings of psychological impact status and factors associated with depression, anxiety and stress among healthcare workers in public hospital in Malaysia during the COVID-19 pandemicNor Asiah Muhamad, Natasha Subhas, Normi Mustapha, et al.JAMA Oncology|January 5, 2023
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA TrialsAranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without LapatinibLisa A Carey, Donald A Berry, Constance T Cirrincione, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissuesDavid L Rimm, Torsten O Nielsen, Scott D Jewell, et al.Nature Communications|November 4, 2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trialsMattia Rediti, Aranzazu Fernandez-Martinez, David Venet, et al.Diseases of the Colon and Rectum|June 15, 2026
Cost-Effectiveness of Pelvic Floor Reconstruction Using Biological Mesh After Extralevator Abdominoperineal resection for Rectal CancerRudolf van den Berg, Gijsbert D Musters, Cornelis Verhoef, et al.Seminars in Cancer Biology|October 13, 2017
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast CancerMaria Vittoria Dieci, Nina Radosevic-Robin, Susan Fineberg, et al.Pageof 35